Eun Hae Estelle Chang1, Waseem Lutfi2,3, Joseph Feinglass4, Alexandra Eudokia Reiher5, Tricia Moo-Young6, Mihir Kiran Bhayani2,3. 1. Department of Otolaryngology Head and Neck Surgery, 981225 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198-1225, USA. Estelle.chang@unmc.edu. 2. Division of Otolaryngology, NorthShore University HealthSystem, Evanston, IL, USA. 3. Pritzker School of Medicine, University of Chicago, Chicago, IL, USA. 4. General Internal Medicine and Geriatrics, Northwestern University Feinberg School of Medicine, 750 N. Lakeshore Dr. 10th Floor, Chicago, IL, 60611, USA. 5. Division of Endocrinology, Department of Medicine, NorthShore University HealthSystem, 2650 Ridge Avenue, Evanston, IL, 60021, USA. 6. Department of Surgery, NorthShore University Health System, 2650 Ridge Avenue, Evanston, IL, 60021, USA.
Abstract
BACKGROUND: Medullary thyroid cancer (MTC) represents the third most common type of thyroid cancer, and the prognosis depends on the stage of the disease at diagnosis and completeness of tumor resection. In 2009, the American Thyroid Association (ATA) published guidelines with evidence-based recommendations for the treatment of MTC. This study aimed to determine national adherence rates of the treatment according to the ATA guidelines specific for MTC. METHODS: Patients diagnosed with MTC from 2004 to 2013 were identified from the National Cancer Database. Guideline adherence rates for the treatment of MTC before and after the publication of ATA guidelines were analyzed and compared to determine patient and clinical variables that affected treatment. RESULTS: A total of 3693 patients diagnosed with MTC were identified. We found 60.3 % of the patients had localized MTC and 39.7 % had regional metastases. Older age, female sex and having Medicaid or being uninsured were directly correlated with more advanced disease upon diagnosis (p < 0.001). Overall, a greater proportion of patients received care in accordance with the recommendations following the ATA guidelines' publication in 2009: 61.4 % of patients treated between 2004 and 2008 versus 66.8 % of patients treated between 2009 and 2013 received care in accordance with the recommendations (p < 0.01). Factors such as older age, African American race, localized disease at diagnosis, lower estimated median zip code household income and being treated in a community versus an academic hospital were associated with a lower likelihood of receiving care in accordance with the guidelines. CONCLUSION: Adherence rates to the ATA recommendations for the treatment of MTC increased modestly following the publication of guidelines in 2009 with the largest increase seen in community hospitals. Being older, African American, diagnosed with localized disease and treated in a community hospital rather than in an academic institution was correlated with a lower likelihood of receiving treatment in accordance with the guidelines. Efforts should be made to continuously increase the adherence rates to the MTC ATA guidelines and to decrease socioeconomic disparities that continue to exist in the treatment of MTC.
BACKGROUND: Medullary thyroid cancer (MTC) represents the third most common type of thyroid cancer, and the prognosis depends on the stage of the disease at diagnosis and completeness of tumor resection. In 2009, the American Thyroid Association (ATA) published guidelines with evidence-based recommendations for the treatment of MTC. This study aimed to determine national adherence rates of the treatment according to the ATA guidelines specific for MTC. METHODS:Patients diagnosed with MTC from 2004 to 2013 were identified from the National Cancer Database. Guideline adherence rates for the treatment of MTC before and after the publication of ATA guidelines were analyzed and compared to determine patient and clinical variables that affected treatment. RESULTS: A total of 3693 patients diagnosed with MTC were identified. We found 60.3 % of the patients had localized MTC and 39.7 % had regional metastases. Older age, female sex and having Medicaid or being uninsured were directly correlated with more advanced disease upon diagnosis (p < 0.001). Overall, a greater proportion of patients received care in accordance with the recommendations following the ATA guidelines' publication in 2009: 61.4 % of patients treated between 2004 and 2008 versus 66.8 % of patients treated between 2009 and 2013 received care in accordance with the recommendations (p < 0.01). Factors such as older age, African American race, localized disease at diagnosis, lower estimated median zip code household income and being treated in a community versus an academic hospital were associated with a lower likelihood of receiving care in accordance with the guidelines. CONCLUSION: Adherence rates to the ATA recommendations for the treatment of MTC increased modestly following the publication of guidelines in 2009 with the largest increase seen in community hospitals. Being older, African American, diagnosed with localized disease and treated in a community hospital rather than in an academic institution was correlated with a lower likelihood of receiving treatment in accordance with the guidelines. Efforts should be made to continuously increase the adherence rates to the MTC ATA guidelines and to decrease socioeconomic disparities that continue to exist in the treatment of MTC.
Authors: Nancy Krieger; Jarvis T Chen; Pamela D Waterman; Mah-Jabeen Soobader; S V Subramanian; Rosa Carson Journal: Am J Epidemiol Date: 2002-09-01 Impact factor: 4.897
Authors: Hans H G Verbeek; Johannes A A Meijer; Wouter T Zandee; Kelvin H Kramp; Wim J Sluiter; Johannes W Smit; Job Kievit; Thera P Links; John Th M Plukker Journal: Ann Surg Oncol Date: 2014-10-15 Impact factor: 5.344
Authors: Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti; Cord Sturgeon Journal: Ann Surg Date: 2007-09 Impact factor: 12.969
Authors: Parisa Tehranifar; Alfred I Neugut; Jo C Phelan; Bruce G Link; Yuyan Liao; Manisha Desai; Mary Beth Terry Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-09-29 Impact factor: 4.254
Authors: Karl Y Bilimoria; David J Bentrem; John G Linn; Andrew Freel; Jen Jen Yeh; Andrew K Stewart; David P Winchester; Clifford Y Ko; Mark S Talamonti; Cord Sturgeon Journal: Surgery Date: 2007-11-05 Impact factor: 3.982
Authors: Ian Mitchell; Edward H Livingston; Alice Y Chang; Shelby Holt; William H Snyder; Ildiko Lingvay; Fiemu E Nwariaku Journal: Surgery Date: 2007-12 Impact factor: 3.982